Literature DB >> 6301521

Carbon tetrachloride-induced hepatic fibrosis and cirrhosis in the developing rat: an experimental model of cirrhosis in childhood.

P Trivedi, A P Mowat.   

Abstract

An experimental animal model designed specifically to simulate liver fibrosis and cirrhosis in childhood is described. Phenobarbitone was administered continuously from the 4th day of life and carbon tetrachloride intermittently from the 13th day to developing rats for 10 weeks. Treated animals showed hepatic necrosis, hepatic regeneration and a progressive increase in hepatic fibrosis; cirrhosis developed before the animals reached sexual maturity at 72 days or were fully grown. Hepatic prolyl hydroxylase activity increased to a maximum level after 20 days of treatment, before increased hepatic collagen could be detected, and fell to a lower level as cirrhosis became established. Serum activities of alkaline phosphatase, aspartate aminotransferase and alanine aminotransferase gave a similar pattern, a marked increase at 20 days of age followed by a fall to near normal levels as hepatic damage became more severe. By the 26th day of life hepatic collagen levels were increased significantly and rose thereafter progressively as fibrosis became more widespread throughout the liver. Cirrhosis developed between the 38th and 75th days. Cirrhosis remained 10 weeks after discontinuation of treatment with phenobarbitone and carbon tetrachloride treatment.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6301521      PMCID: PMC2040776     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  18 in total

1.  Adaptive increases in drug-metabolizing enzymes induced by phenobarbital and other drugs.

Authors:  A H CONNEY; C DAVISON; R GASTEL; J J BURNS
Journal:  J Pharmacol Exp Ther       Date:  1960-09       Impact factor: 4.030

2.  Micromethod for the direct determination of serum triglycerides.

Authors:  E VAN HANDEL; D B ZILVERSMIT
Journal:  J Lab Clin Med       Date:  1957-07

3.  A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases.

Authors:  S REITMAN; S FRANKEL
Journal:  Am J Clin Pathol       Date:  1957-07       Impact factor: 2.493

4.  Modifications of a specific assay for hydroxyproline in urine.

Authors:  K I Kivirikko; O Laitinen; D J Prockop
Journal:  Anal Biochem       Date:  1967-05       Impact factor: 3.365

Review 5.  Prolyl hydroxylase.

Authors:  G J Cardinale; S Udenfriend
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1974

Review 6.  Carbon tetrachloride hepatotoxicity.

Authors:  R O Recknagel
Journal:  Pharmacol Rev       Date:  1967-06       Impact factor: 25.468

7.  Instant cirrhosis. An improved method for producing cirrhosis of the liver in rats by simultaneous administration of carbon tetrachloride and phenobarbitone.

Authors:  E K McLean; A E McLean; P M Sutton
Journal:  Br J Exp Pathol       Date:  1969-10

8.  Purification and properties of collagen proline hydroxylase from newborn rat skin.

Authors:  R E Rhoads; S Udenfriend
Journal:  Arch Biochem Biophys       Date:  1970-08       Impact factor: 4.013

9.  Necrogenic action of carbon tetrachloride in the rat: a speculative mechanism based on activation.

Authors:  T F Slater
Journal:  Nature       Date:  1966-01-01       Impact factor: 49.962

10.  Effect of colchicine on collagen, albumin and transferrin synthesis by cirrhotic rat liver slices.

Authors:  M Rojkind; D Kershenobich
Journal:  Biochim Biophys Acta       Date:  1975-02-10
View more
  2 in total

1.  Agaricus blazei Murill as an efficient hepatoprotective and antioxidant agent against CCl4-induced liver injury in rats.

Authors:  Abeer M Al-Dbass; Sooad K Al-Daihan; Ramesa Shafi Bhat
Journal:  Saudi J Biol Sci       Date:  2012-04-01       Impact factor: 4.219

2.  MicroRNA-503 Targets Mothers Against Decapentaplegic Homolog 7 Enhancing Hepatic Stellate Cell Activation and Hepatic Fibrosis.

Authors:  Xia Xie; Cheng-Yun Dou; Yu Zhou; Quan Zhou; Hai-Bo Tang
Journal:  Dig Dis Sci       Date:  2020-07-09       Impact factor: 3.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.